Dashboard
Manage Tickers

PFE PFIZER INC

NYSE pfizer.com


$ 24.69 $ 0.00 (0 %)    

Thursday, 06-Nov-2025 04:53:54 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 623.48 $ 0.00 (0 %)
DIA $ 473.03 $ 0.00 (0 %)
SPY $ 677.87 $ 0.00 (0 %)
TLT $ 89.10 $ 0.00 (0 %)
GLD $ 368.95 $ 0.00 (0 %)
$ 24.61
$ 24.36
$ 24.68 x 363
$ 24.70 x 20
-- - --
$ 20.18 - $ 27.69
107,240,924
na
139.93B
$ 0.50
$ 14.24
TBD
na
na ($ 0.07)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-28-2025 10-Q
2 08-05-2025 06-29-2025 10-Q
3 05-05-2025 03-30-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-04-2024 09-29-2024 10-Q
6 08-05-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 11-08-2023 10-01-2023 10-Q
10 08-09-2023 07-02-2023 10-Q
11 05-10-2023 04-02-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-09-2022 10-02-2022 10-Q
14 08-10-2022 07-03-2022 10-Q
15 05-11-2022 04-03-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-12-2021 10-03-2021 10-Q
18 08-12-2021 07-04-2021 10-Q
19 05-13-2021 04-04-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-27-2020 10-Q
22 08-06-2020 06-28-2020 10-Q
23 05-07-2020 03-29-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 11-07-2019 09-29-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-09-2018 07-01-2018 10-Q
31 05-10-2018 04-01-2018 10-Q
32 02-22-2018 12-31-2017 10-K
33 11-09-2017 10-01-2017 10-Q
34 08-10-2017 07-02-2017 10-Q
35 05-11-2017 04-02-2017 10-Q
36 02-23-2017 12-31-2016 10-K
37 11-10-2016 10-02-2016 10-Q
38 08-11-2016 07-03-2016 10-Q
39 05-12-2016 04-03-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Reported Earlier, 'Pfizer Matches Novo Bid...
11/06/2025 09:15:19

https://www.ft.com/content/ae3297f3-4dd1-4c8a-b9c5-9c3717d34c52 

Core News & Articles
Reported Earlier, Metsera Issues Statement...
11/06/2025 08:41:37

"Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restrai...

pfizer-responds-to-delaware-chancery-court-ruling-said-we-remain-confident-in-the-merits-of-our-claims-and-our-belief-that-metsera-has-acted-in-breach-of-its-contractual-obligations
Pfizer Responds To Delaware Chancery Court...
11/05/2025 22:13:12

Core News & Articles
The Wall Street Journal Reported Pfizer Pr...
11/05/2025 21:55:02

Core News & Articles
Novo Nordisk, In A Statement, Says Its Met...
11/05/2025 20:26:03

Core News & Articles
Watching Novo Nordisk, Pfizer, Metsera; Tr...
11/05/2025 20:25:21

Core News & Articles
Metsera Estimates Value Of Pfizer's Latest...
11/05/2025 19:11:32

-Reuters Citing Metsera Letter To Court

Core News & Articles
Pfizer Has Removed Conditions On Sale Of A...
11/05/2025 19:10:18

-Reuters Citing Letter To Court

Core News & Articles
10 Health Care Stocks Whale Activity In To...
11/05/2025 17:35:20

novo-pfizer-are-battling-to-buy-the-future-of-weight-loss--but-viking-already-owns-it
Novo, Pfizer Are Battling To Buy The Futur...
11/04/2025 20:04:42

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nor...

pfizer-novo-nordisk-intensify-fight-for-metsera-as-buyout-offers-continue-to-climb
Pfizer, Novo Nordisk Intensify Fight For M...
11/04/2025 19:45:55

Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escala...

pfizer-q3-revenue-trends-remain-uneven-cost-cuts-drive-earnings
Pfizer Q3 Revenue Trends Remain Uneven, Co...
11/04/2025 18:25:49

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," accordin...

palantir-weighs-on-wall-street-bitcoin-slumps-5-whats-moving-markets-tuesday
Palantir Weighs On Wall Street, Bitcoin Sl...
11/04/2025 18:22:32

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, o...

Core News & Articles
Pfizer CEO Says Our Bid For Metsera Has Ta...
11/04/2025 15:52:10

-Reuters Citing Conf. Call

dow-dips-over-400-points-pfizer-earnings-top-estimates
Dow Dips Over 400 Points; Pfizer Earnings ...
11/04/2025 14:53:19

pfizers-core-drugs-offset-covid-revenue-drop-lifts-2025-profit-outlook-despite-tariffs
Pfizer's Core Drugs Offset COVID Revenue D...
11/04/2025 14:22:21

Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID ...

Core News & Articles
Pursuant To Pfizer Merger Agreement, Metse...
11/04/2025 14:12:57

Core News & Articles
Metsera Receives Amended Proposal From Nov...
11/04/2025 14:11:56

pfizer-q3-revenues-higher-for-eliquis-vyndaqel-and-nurtec-odtvydura-offset-by-lower-revenues-for-paxlovid-and-comirnaty
Pfizer Q3 Revenues Higher For Eliquis, Vyn...
11/04/2025 11:48:54

pfizer-raises-fy2025-adj-eps-guidance-from-290-310-to-300-315-vs-304-est-affirms-fy2025-sales-guidance-of-61000b-64000b-vs-62879b-est
Pfizer Raises FY2025 Adj EPS Guidance from...
11/04/2025 11:45:49

Pfizer (NYSE:PFE) raises FY2025 Adj EPS guidance from $2.90-$3.10 to $3.00-$3.15 vs $3.04 analyst estimate. Affirms FY2025 sale...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION